Published in Prostate Cancer Prostatic Dis on January 01, 2001
Identification and expression analysis of ras gene in silkworm, Bombyx mori. PLoS One (2009) 0.85
Manumycin induces apoptosis in prostate cancer cells. Onco Targets Ther (2014) 0.81
Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A (1984) 6.45
Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell (1997) 5.73
Cloning of bovine GAP and its interaction with oncogenic ras p21. Nature (1988) 5.56
PDGF induction of tyrosine phosphorylation of GTPase activating protein. Nature (1989) 4.36
Tumors secreting human TNF/cachectin induce cachexia in mice. Cell (1987) 4.19
Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell (1983) 4.13
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res (2000) 3.75
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (2011) 3.59
Mutant ras-encoded proteins with altered nucleotide binding exert dominant biological effects. Proc Natl Acad Sci U S A (1986) 3.59
Differential expression of myc family genes during murine development. Nature (1986) 3.57
Multiferroic BaTiO3-CoFe2O4 Nanostructures. Science (2004) 3.49
Human N-myc is closely related in organization and nucleotide sequence to c-myc. Nature (1986) 3.40
Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer (1998) 3.32
Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem (1998) 3.25
Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product. Nature (1991) 3.20
Identification of effector residues and a neutralizing epitope of Ha-ras-encoded p21. Proc Natl Acad Sci U S A (1986) 3.11
Sequence dependence of protein isoprenylation. J Biol Chem (1991) 3.10
Molecular analysis of the envelope gene and long terminal repeat of Friend mink cell focus-inducing virus: implications for the functions of these sequences. J Virol (1984) 3.09
S. cerevisiae genes IRA1 and IRA2 encode proteins that may be functionally equivalent to mammalian ras GTPase activating protein. Cell (1990) 3.09
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res (2001) 3.02
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A (2005) 2.93
Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol (1999) 2.91
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A (1996) 2.90
Yeast and mammalian ras proteins have conserved biochemical properties. Nature (1985) 2.85
Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol (2001) 2.80
CDC25: a component of the RAS-adenylate cyclase pathway in Saccharomyces cerevisiae. Science (1987) 2.67
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol (1988) 2.63
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer (1989) 2.62
Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (1993) 2.60
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol (1985) 2.56
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol (1993) 2.49
Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science (1984) 2.46
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res (1998) 2.43
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42
Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst (2001) 2.41
Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst (1998) 2.39
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol (1999) 2.38
Structure and expression of the murine N-myc gene. Proc Natl Acad Sci U S A (1986) 2.36
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35
Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F. Mol Cell Biol (1993) 2.34
N-myc can cooperate with ras to transform normal cells in culture. Proc Natl Acad Sci U S A (1985) 2.33
Characterization of the retinoblastoma binding proteins RBP1 and RBP2. Oncogene (1993) 2.20
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
Suppressors of the ras2 mutation of Saccharomyces cerevisiae. Genetics (1986) 2.15
A C-terminal domain of GAP is sufficient to stimulate ras p21 GTPase activity. EMBO J (1989) 2.14
Use of Arabidopsis mutants and genes to study amide amino acid biosynthesis. Plant Cell (1995) 2.12
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res (2001) 2.08
A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res (1995) 2.04
A study of sexual behavior among rural residents of China. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 2.02
The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci (2008) 2.00
Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J Biol Chem (1995) 1.98
Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. Br J Ophthalmol (2010) 1.98
Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol (1997) 1.94
Species identification and subtyping of Ureaplasma parvum and Ureaplasma urealyticum using PCR-based assays. J Clin Microbiol (2000) 1.94
Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci U S A (1987) 1.92
Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer (1994) 1.88
Age-related changes in human lens crystallins identified by two-dimensional electrophoresis and mass spectrometry. Exp Eye Res (1998) 1.88
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res (2000) 1.87
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol (1993) 1.86
Sequence analysis of betaA3, betaB3, and betaA4 crystallins completes the identification of the major proteins in young human lens. J Biol Chem (1997) 1.84
The ras oncogene--an important regulatory element in lower eucaryotic organisms. Microbiol Rev (1989) 1.79
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol (1994) 1.78
Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res (2000) 1.75
Identification of guanine nucleotides bound to ras-encoded proteins in growing yeast cells. J Biol Chem (1987) 1.74
Subgenomic fragment of molecular cloned Friend murine leukemia virus DNA contains the gene(s) responsible for Friend murine leukemia virus-induced disease. J Virol (1980) 1.73
Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol (2001) 1.72
Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol (1995) 1.70
Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am (1997) 1.70
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med (1998) 1.69
Gamma-S crystallin gene (CRYGS) mutation causes dominant progressive cortical cataract in humans. J Med Genet (2005) 1.68
Autophosphorylation of v-Ha-ras p21 is modulated by amino acid residue 12. Proc Natl Acad Sci U S A (1984) 1.68
Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase. J Biol Chem (1990) 1.68
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol (1997) 1.68
Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem (1986) 1.67
Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell (1994) 1.67
Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol (1989) 1.65
Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein. Mol Cell Biol (1993) 1.64
Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci U S A (1999) 1.63
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst (1999) 1.63
Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras. Mol Cell Biol (1991) 1.62
Isolation of transplantable erythroleukemia cells from mice infected with helper-independent Friend murine leukemia virus. Blood (1981) 1.61
Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest (1995) 1.61
Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res (1990) 1.57
Preferential inhibition of the oncogenic form of RasH by mutations in the GAP binding/"effector" domain. Cell (1991) 1.57
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer (2013) 1.57
Isolation of variants in phagocytosis of a macrophage-like continuous cell line. J Exp Med (1977) 1.54
Transcription factor E2F binds DNA as a heterodimer. Proc Natl Acad Sci U S A (1993) 1.53
A 2.4-kilobase-pair fragment of the Friend murine leukemia virus genome contains the sequences responsible for friend murine leukemia virus-induced erythroleukemia. J Virol (1983) 1.53
Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines. Oncogene Res (1988) 1.53